Strength training:
The mortality data
beyond aesthetics

The primary meta-analysis, Shailendra et al. 2022, pooled data from 16 prospective cohort studies and found a 15% reduction in all-cause mortality for those who engaged in any muscle-strengthening exercise compared to none. A separate dose-response analysis found the largest reduction (27%) at approximately 60 minutes per week, with a U-shaped relationship where very high volumes (>150 minutes per week) showed diminishing or no benefit. The mortality benefit is independent of aerobic physical activity, people who did both resistance and aerobic training had lower mortality than those who did either alone. A 2022 British Journal of Sports Medicine meta-analysis by Momma et al. confirmed these findings across multiple non-communicable diseases, finding associations with reduced cardiovascular disease, cancer, and diabetes risk.

One of the most important and underappreciated findings in this research is how little resistance training is required to capture the majority of the longevity benefit. The dose-response data consistently shows that the largest proportional reduction in mortality risk occurs at modest volumes, two sessions of 30 minutes per week, or equivalent distributions. Beyond approximately 60 minutes per week, additional resistance training produces diminishing returns on mortality outcomes (though it may still produce meaningful benefits for performance, body composition, and metabolic health). This does not mean more training is harmful, the U-shape at very high volumes likely reflects confounding, but it does mean that the minimum effective dose for longevity benefit is achievable by virtually any adult with a functioning schedule.

The longevity benefit of resistance training is not mediated by a single mechanism. Resistance training reduces visceral fat, improves insulin sensitivity and glucose metabolism, lowers resting blood pressure, improves lipid profiles, reduces systemic inflammation, and preserves muscle mass, all of which are independently associated with mortality risk. Muscle mass itself is increasingly recognised as a metabolically important tissue: skeletal muscle is the primary site of glucose disposal and plays a central role in metabolic regulation. Loss of muscle mass with age (sarcopenia) is independently associated with increased mortality risk, and resistance training is the most effective intervention for preventing it. The multi-pathway benefit is why resistance training shows independent association with mortality even after adjusting for other risk factors.

The Shailendra 2022 meta-analysis found a 13% reduction in cancer-specific mortality associated with resistance training. The Momma 2022 meta-analysis in BJSM found that muscle-strengthening activities were associated with reduced incidence of several cancers. The mechanisms are not fully understood but likely include reductions in adiposity, improvements in insulin sensitivity and IGF-1 signalling, reductions in systemic inflammation, and immune function improvements, all of which influence cancer risk through distinct pathways. The cancer mortality data is less robust than the all-cause and cardiovascular data due to smaller sample sizes and inconsistent results across cancer types, but the direction of evidence is consistently favourable.

Recent data from the CLINIMEX Exercise cohort (3,889 adults, median follow-up 10.8 years) found that relative muscle power, the ability to generate force quickly, as measured by upper row power adjusted for body weight, was a stronger predictor of mortality than muscle strength alone. In multivariable analysis, the hazard ratios for mortality comparing the lowest to highest categories of relative muscle power were 5.88 for men and 6.90 for women, among the largest mortality risk differentials in any physical fitness study. This finding connects directly to the broader power decline literature: as people age, power deteriorates faster than strength, and the functional and survival consequences are large. Training programmes that preserve power, through explosive intent, velocity-based training, and power-emphasis movements, address this specific risk.

The research defining muscle-strengthening activity is broad: it includes free weights, machines, bodyweight exercises, resistance bands, and any training that progressively challenges muscles against external resistance. The studies showing mortality benefit do not require training at high intensity or with heavy loads. the key variable is progressive overload: consistently challenging the muscles enough to stimulate adaptation. Functional training, compound movements (squat, deadlift, hinge, push, pull patterns), and exercises that develop strength across a range of motion are all appropriate. The evidence does not support one specific training modality over others for longevity purposes; consistency and progressive challenge are the determining variables.

The most consistent finding across the large prospective cohort studies is that people who engage in both resistance training and aerobic exercise have lower mortality than those who do either alone. A large Oxford cohort study found that both weight training and aerobic exercise were independently associated with lower all-cause, cardiovascular, and cancer mortality, and that people engaging in both had the lowest mortality risk of any exercise group. This does not mean you need to be doing both every day or at high volume, the dose-response data suggests relatively modest amounts of each are sufficient to capture the majority of the benefit. The message is not to prioritise one over the other but to include both as foundational components of a physical training programme.